Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Platinum-Etoposide in LCNEC
NCT06393816Phase 2Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jun 2024
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
A Phase 2 trial of durvalumab in large cell neuroendocrine carcinoma of the lung (LCNEC), sponsored by Centre Léon Bérard. Started Jun 2024; status: recruiting.
02
Drugs
durvalumab
03
Conditions
large cell neuroendocrine carcinoma of the lung (LCNEC)
Beyond the preview
Go deeper on NCT06393816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393816.